Evidence map›Paper›PMID 34626100›Full record

ArticleBiotechnology progress2022

Biophysical properties of tense quaternary state polymerized human hemoglobins bracketed between 500 kDa and 0.2 μm in size.

Clayton T Cuddington, Savannah R Wolfe, Andre F Palmer

Abstract read
In one paragraph

Article in Biotechnology progress, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Hemoglobin-based oxygen carriers with antioxidant properties.Journal of materials chemistry. B · 2026
    Article
  3. Acellular Hemoglobin Impairs Cardiomyocyte Excitation-Contraction Coupling.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Clayton T CuddingtonWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0001-8739-2155
Savannah R WolfeWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.

Funding

PEGylated megahemoglobin for use as a red blood cell substituteR01HL138116 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, KAUMAYA, PRAVIN T. P. · 2017 to 2020
$2.9M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Engineering a novel biomaterial for oxygen transport applicationsR01HL156526 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, PALMER, ANDRE FRANCIS · 2021 to 2024
$2.5M
Attenuating the Oxidative and Myocardial Side-Effects of Acellular HemoglobinR01HL126945 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.7M
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic BioreactorsR01EB021926 · NIBIB · OHIO STATE UNIVERSITY · PI BERTHIAUME, FRANCOIS, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.4M
NHLBI NIH HHS R01 HL126945NHLBI NIH HHS R01 HL138116NHLBI NIH HHS R01 HL156526NHLBI NIH HHS R01 HL162120NIBIB NIH HHS R01 EB021926
6 · The paper itself

Abstract

Polymerized hemoglobin (Hb)-based oxygen carriers (HBOCs) are a scalable and cost-effective red blood cell (RBC) substitute. However, previous generations of commercial polymerized HBOCs elicited oxidative tissue injury in vivo due to the presence of low molecular weight polymeric Hb species (<500 kDa) and cell-free Hb (64 kDa). Polymerized human Hb (PolyhHb) locked in the tense quaternary state (T-state) exhibits great promise to meet clinical needs where past polymerized HBOCs failed. This work shows that separation of T-state PolyhHb via a two-stage tangential flow filtration (TFF) purification train such that the Hb polymers are bracketed between 500 kDa and 0.2 μm creates a uniform polymer size and largely eliminates the Hb species which elicit deleterious side effects in vivo. Biophysical characterization of these materials demonstrates their potential effectiveness as an RBC substitute and verifies the low percentage of low molecular weight Hb polymers and cell-free Hb. Size exclusion chromatography confirms that T-state PolyhHb can be consistently produced in a size range between 500 kDa and 0.2 μm. Furthermore, the average molecular weight of all PolyhHb species produced is one or two orders of magnitude larger than that of the commercial polymerized HBOCs Hemolink and Oxyglobin, respectively. Haptoglobin binding kinetics confirms that two-stage TFF processing of PolyhHb reliably removes cell-free Hb and low molecular weight polymeric Hb species. T-state PolyhHbs demonstrate lower auto-oxidation rates compared to unmodified Hb and prior generations of commercial polymerized HBOCs. These results demonstrate T-state PolyhHb's feasibility as a next-generation polymerized HBOC for potential use in transfusion medicine.

Indexed as

Blood SubstitutesHemoglobinsHumansOxygenPolymerizationPolymersBlood SubstitutesHemoglobinsOxygenPolymershemoglobin-based oxygen carrieroxygen therapeuticpolymerized hemoglobinred blood cell substitutetangential flow filtration

Identifiers

PMID34626100
PMCPMC8854340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.